MedTrace Logo

Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS

NCT02827656 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-07-12

No results posted yet for this study

Summary

The purpose of this study is to compare two luteal support protocols in In vitro fertilization patients (IVF) and are at risk of developing ovarian hyperstimulation syndrome (OHSS). We would like to determine whether luteal Decapeptyl on days 3, 6,9 post ovulation triggering is as good as low dose hCG on day 3 post triggering..

Conditions

Interventions

DRUG

Decapeptyl

luteal support as described and vaginal progesterone 200 mg 3 times a day

DRUG

hCG luteal support

luteal support as described and vaginal progesterone 200 mg 3 times a day

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Amir Wiser, MD · MMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-08-31
Completion
2017-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02827656 on ClinicalTrials.gov